큐리언트

115180KOSDAQ자연과학 및 공학 연구개발업

40.5 / 100

Reference Date: 2026-04-13

Financial Score11.0 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Plunged 30.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Curient is a biotech company specializing in new drug development, established with government and international investments to advance Korea's pharmaceutical and biotech industry. Collaborating with institutions like the French Pasteur Institute and Germany's Max Planck Society, it focuses on infectious disease and oncology/immunology therapies. Partnering with MSD, it develops combination therapies with Keytruda, and reported consolidated sales of 92 billion KRW in 2024.

Number of Employees

32people

Average Salary

141.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

—Industry Average 3.823.5Point

ROE

-68.05Industry Average -32.113.5Point

2.1x industry avg (excellent)

Debt Ratio

48.23Industry Average 7.520.0Point

6.4x industry avg (risky)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.2% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼13.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -57.4% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position6.0Point

52w upper range (61%)

Current 34,750Won52-week high 50,90052-week low 8,570

1-month return0.0Point

1m -30.36% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

11 totalPositive 0Neutral 11Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-03
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-31
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-31
Neutral주식매수선택권부여에관한신고2026-03-26
Neutral정기주주총회결과2026-03-26